Skip to main content

Verquvo Side Effects

Generic name: vericiguat

Medically reviewed by Drugs.com. Last updated on Sep 7, 2022.

Note: This document contains side effect information about vericiguat. Some dosage forms listed on this page may not apply to the brand name Verquvo.

Applies to vericiguat: oral tablet.

Warning

Oral route (Tablet)

Embryo-Fetal Toxicity: Females of reproductive potential: Exclude pregnancy before the start of treatment. To prevent pregnancy, females of reproductive potential must use effective forms of contraception during treatment and for 1 month after stopping treatment. Do not administer vericiguat to a pregnant female because it may cause fetal harm.

Serious side effects of Verquvo

Along with its needed effects, vericiguat (the active ingredient contained in Verquvo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking vericiguat:

More common

  • Blurred vision
  • confusion
  • dizziness, faintness, or lightheadedness when getting up suddenly from a lying or sitting position
  • pale skin
  • sweating
  • trouble breathing
  • unusual bleeding or bruising
  • unusual tiredness or weakness

For Healthcare Professionals

Applies to vericiguat: oral tablet.

Cardiovascular

Very common (10% or more): Hypotension (included blood pressure decreased, diastolic blood pressure decreased, systolic blood pressure decreased, hypotension, orthostatic hypotension; up to 16.4%)

Common (1% to 10%): Symptomatic hypotension, orthostatic hypotension

Frequency not reported: Systolic blood pressure reduced[Ref]

During the study, the mean reduction in systolic blood pressure was about 1 to 2 mmHg greater in patients who received this drug compared with placebo. In the study, hypotension was reported in 16.4% of patients using this drug; this also included orthostatic hypotension, which was reported in 1.3% of patients. Symptomatic hypotension was reported in 9.1% of patients using this drug and was considered a serious adverse event in 1.2% of patients.[Ref]

Hematologic

Common (1% to 10%): Anemia (included anemia, macrocytic anemia, anemia of chronic disease, autoimmune hemolytic anemia, blood loss anemia, hemolytic anemia, hypochromic anemia, iron deficiency anemia, microcytic anemia, nephrogenic anemia, normochromic anemia, normochromic normocytic anemia, normocytic anemia, pancytopenia, pernicious anemia, hematocrit decreased, hemoglobin decreased, RBC count decreased)[Ref]

Nervous system

Common (1% to 10%): Dizziness, headache[Ref]

Gastrointestinal

Common (1% to 10%): Nausea, dyspepsia, vomiting, gastroesophageal reflux disease[Ref]

References

1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

2. Cerner Multum, Inc. "Australian Product Information." O 0

3. "Product Information. Verquvo (vericiguat)." Merck & Company Inc (2021):

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.